Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Appeals Federal Court Denial of Preliminary Injunction Against Ariosa

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market on Monday that it has appealed a decision by a federal court denying Sequenom's request for a preliminary injunction against Ariosa Diagnostics.

The US District Court for the Northern District of California denied Sequenom's motion for a preliminary injunction against Ariosa, filed in February, earlier this month. Sequenom had requested the court prevent Ariosa from offering or selling its Harmony Prenatal Test.

Sequenom sued Ariosa, formerly called Aria Diagnostics, in January alleging Ariosa's prenatal trisomy test infringes its patent, US Patent No. 6,258,540. Ariosa had earlier sued Sequenom claiming that the firm is overly aggressive in enforcing a broad patent related to the use of circulating cell-free DNA in maternal plasma to diagnose fetal aneuploidies.

Sequenom launched its trisomy 21 test called MaterniT21 Plus in October. Ariosa launched its Harmony Prenatal Test nationwide in May through Laboratory Corporation of America.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.